Tiny Float and Bullish Momentum: Why Quantum BioPharma (NASDAQ: QNTM) Should be On Your Radar Tomorrow

*Sponsored by Quantum BioPharma Ltd Quantum BioPharma (NASDAQ: QNTM) Could Be One to Watch Closely Tomorrow Morning! Quantum BioPharma (NASDAQ: QNTM) Comes Backed by Several  Potential Catalysts Including: Quantum BioPharma (NASDAQ: QNTM) has a float of under 1.7Mn shares following a recent reverse split, potentially leading to significant shifts if demand begins to change. Shares Quantum BioPharma (NASDAQ: QNTM) have moved approximately 57% in the past week, surpassing key moving averages and marking a 93% (approx) move since early October 2024. Quantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, a treatment for multiple sclerosis, positioning itself in the rapidly growing MS market expected to reach $38B by 2032. The company’s unbuzzd™ product is a breakthrough in alcohol detoxification, with distribution expanding through major retailers like Walmart and CVS. Endorsed by Kevin Harrington and backed by a major distribution deal, unbuzzd™ is rapidly expanding across Puerto Rico, the Caribbean, and parts of Central and South America. October 22, 2024 Dear Reader, On Monday, a little-known company made headlines by filing a $700Mn lawsuit against several major financial institutions, accusing them of manipulating its price through a multi-year "spoofing" scheme.  This bold legal move could be the catalyst for significant future developments. Quantum BioPharma (NASDAQ: QNTM) could be one to watch closely tomorrow. Following a reverse split, Quantum BioPharma (NASDAQ: QNTM) has a very limited float, with less than 1.7Mn shares currently available.  Over the past week, it has moved approximately 57%, surpassing several key technical levels—including the 5-Day, 20-Day, and 50-Day moving averages— reaching $7.27 today, marking a 93% (approx) move since 10/1/2024. According to TradingView, Quantum BioPharma (NASDAQ: QNTM) is currently triggering Bullish on the Momentum indicator as of today, 10/22. Could this be the beginning of something much bigger? With a market cap under $12M, it has remained under the radar for now, but that may not last long. Make sure you consider adding Quantum BioPharma (NASDAQ: QNTM) to the top of your watchlist before tomorrow morning. Quantum BioPharma (NASDAQ: QNTM) is pioneering the development of transformative treatments aimed at addressing some of the most pressing medical challenges, including neurodegenerative disorders, metabolic conditions, and al-co-hol misuse.  Their diverse pipeline of therapeutic candidates highlights their commitment to tackling these complex health issues, with multiple projects advancing through various stages of clinical development. Through its wholly owned subsidiary, Lucid Ps-yche-ceu-ticals Inc.,Quantum BioPharma (NASDAQ: QNTM) is taking significant strides in the development of its flagship compound, Lucid-MS, which is positioned to make a critical impact on the treatment of multiple sclerosis (MS).  MS is a chronic condition that affects the central nervous system, leading to debilitating symptoms like severe fatigue, coordination problems, and speech issues.  Nearly 1Mn people in the United States and around 2.8Mn globally are living with this life-altering disease, according to the National Multiple Sclerosis Society. The market for multiple sclerosis therapies is projected to experience substantial growth in the coming years, increasing from approximately $21B in 2024 to nearly $38B by 2032.  This growing demand underscores the urgent need for new, effective treatments for this disease, and Quantum BioPharma (NASDAQ: QNTM), through its work on Lucid-MS, is well-positioned to capture attention as the field evolves. With its strong portfolio of cutting-edge treatments and a focus on addressing severe medical conditions affecting millions, Quantum BioPharma (NASDAQ: QNTM) is emerging as a key player in the biopharmaceutical landscape, making it a company worth following closely. Lucid-MS is specifically developed to target the underlying mechanism of multiple sclerosis by preventing myelin degradation and working to restore damaged myelin.  As myelin acts as a protective covering for nerve fibers, its deterioration is a key contributor to MS.  Preclinical data suggest that Lucid-MS has the ability to halt or reverse this damage, providing a potential new treatment for those suffering from MS and other neurodegenerative disorders. Tackling Al-co-hol Misuse   Beyond its focus on neurodegenerative conditions, Quantum BioPharma (NASDAQ: QNTM) has innovated in the realm of al-co-hol misuse with unbuzzd™, a product designed to promote mental clarity and support faster alcohol metabolism.  This novel approach bridges the gap between science and alcohol detoxification, addressing a critical public health concern. unbuzzd™ was introduced to the market by Celly Nutrition Corp., a Quantum BioPharma (NASDAQ: QNTM) spin-off that holds a 25.71% stake.  In 2023, unbuzzd™ secured a major distribution deal with FUSION Distribution Group, granting access to markets across Puerto Rico, the Caribbean, and Central and South America.  The product, currently available on Amazon in powder form, will soon expand into Ready-to-Drink cans and reach retailers like Walmart and CVS, positioning unbuzzd™ for further growth. Unbuzzd™: A Breakthrough in Alcohol Detox Solutions  Quantum BioPharma (NASDAQ: QNTM) has introduced unbuzzd™, a cutting-edge product designed to accelerate alcohol metabolism and promote mental clarity after consumption.  This innovative solution addresses a growing need within the health and wellness industry, offering an effective way to manage alcohol detoxification. Endorsed by Kevin Harrington, the original “Shark” from Shark Tank and a renowned figure in health and wellness, unbuzzd™ has received glowing praise for its potential to revolutionize alcohol detox.  Harrington, known for his expertise in breakthrough products, shared his enthusiasm, stating, “I witnessed firsthand how unbuzzd™ transformed someone’s behavior after alcohol consumption. The results were remarkable—this product could truly change how we approach alcohol detoxification.” Quantum BioPharma (NASDAQ: QNTM) continues to push the boundaries in research and development, working on breakthrough treatments for multiple sclerosis, neurodegenerative disorders, and alcohol misuse.  Their commitment to innovation places them at the forefront of addressing critical health issues. 5 reasons to consider adding Quantum BioPharma (NASDAQ: QNTM) to your radar  before tomorrow… 1. Tiny Float: Quantum BioPharma (NASDAQ: QNTM)’s recent reverse split has left it with a reduced float of fewer than 1.7Mn shares, which could lead to significant movement as interest builds. The reduced availability of shares could result in noticeable price shifts based on demand. 2. Bullish Momentum: Shares of Quantum BioPharma (NASDAQ: QNTM) moved approximately 57% in the past week, trending above key technical indicators such as the 5-Day, 20-Day, and 50-Day moving averages. This momentum suggests the potential for continued momentum as it reached $7.27 today, marking an approximate 93% move since early October 2024. 3. Breakthrough Treatment: Quantum BioPharma (NASDAQ: QNTM) is at the forefront of addressing multiple sclerosis (MS) through its development of Lucid-MS, a compound designed to prevent and reverse myelin degradation. With the global market for MS treatments expected to grow from $21B in 2024 to $38B by 2032, this development places Quantum BioPharma in a unique position within a rapidly expanding field. 4. Innovative Product for Alcohol Detoxification: Beyond neurodegenerative research, Quantum BioPharma (NASDAQ: QNTM)’s unbuzzd™ product represents a breakthrough in alcohol detoxification and mental clarity. With growing health and wellness sector interest, unbuzzd™ is expanding its reach through major distribution channels like Walmart and CVS, potentially increasing visibility and growth. 5. Strategic Industry Partnerships and Endorsements: Endorsed by Kevin Harrington from Shark Tank and backed by a major distribution deal with FUSION Distribution Group, unbuzzd™ has secured a strong foothold in the market. Its expansion into new regions, including Puerto Rico, the Caribbean, and Central and South America, signals that Quantum BioPharma (NASDAQ: QNTM) is rapidly broadening its influence in both biopharmaceutical and health product spaces. To wrap up, Quantum BioPharma (NASDAQ: QNTM) is demonstrating strong potential, starting with its tiny float that could lead to significant movement if demand builds. With an approximate 57% move in the past week and shares trending above key technical indicators, the potential for continued bullish momentum is there.  The company’s pioneering work with Lucid-MS in the growing multiple sclerosis market, alongside the innovative unbuzzd™ product for al-co-hol detoxification, highlights its focus on addressing pressing health needs.  With major distribution deals and endorsements like Kevin Harrington’s, Quantum BioPharma (NASDAQ: QNTM)  is rapidly expanding its reach, making it one company to keep on your radar. Take a look at (QNTM) before tomorrow morning. Have a good night.  Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/ *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 10/22/2024 and ending on 10/23/2024 to publicly disseminate information about (QNTM:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”) to disseminate information about (QNTM:US) via digital communications. To date Headline Media LLC has been paid twenty thousand USD (“Funds”). Neither Headline Media or its members own shares of (QNTM:US). Please see important disclosure information here: https://marketcrux.com/qntm-disclosure-v2/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice